UNSPSC 51121915: Bufogenin or resibufogenin

This classification denotes an enzyme inhibitor with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K654P2M4J, chemically known as 14,15beta-epoxy-3beta-hydroxy-5beta-bufa-20,22-dienolide but generally known as bufogenin, which bears US NIH Compound Identifier 10063. European Medicines Agency schedules Bufogenin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05964MIG. The term BUFOGENIN is an International Non-Proprietary Name.

BUFOGENIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Bufogenin or resibufogenin bears US NLM identifiers UMLS ID C0054208 and NCI Concept Code C77829. SMILES: CC12CCC(CC1CCC3C2CCC4(C35C(O5)CC4C6=COC(=O)C=C6)C)O.

UNSPSC 51121915 Bufogenin or resibufogenin is a Commodity code that in practice captures state and local procurement of advanced life support and emergency medications, pharmaceutical supply agreements, and generic multi-source pharmaceuticals for public health agencies and cooperative purchasing networks. State and local governments buy under this code primarily through fire rescue departments, health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across dozens of participating jurisdictions. The work ranges from discrete sealed-bid procurements for specific medication line items (such as epinephrine, labetalol, adenosine, and diltiazem for emergency medical response) to broader RFPs for generic pharmaceutical supply agreements administered through authorized wholesalers and subject to cGMP and Drug Supply Chain Security Act compliance. Issuing bodies include municipal purchasing departments, state health agencies, and cooperative purchasing entities like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP); the code shows little vendor concentration, with opportunities distributed across purchasing mechanisms designed to serve multiple participating jurisdictions simultaneously.

The code shows recent activity across Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB No. 26P00188 on April 24, 2026 for Advanced Life Support Medications (due April 8, 2026) with an estimated contract value of $40,000, requiring supply of four specific medication line items for Tampa Fire Rescue with nine-month minimum shelf life and SLBE sheltered market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional PBM and GPO channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 10 percent on fixed pricing, requiring vendors to maintain insurance coverage of $5 million general liability and comply with one-year minimum expiration and six-month shelf-life requirements.